Loading...
•
Dec 31, 2023
Bioxcel Therapeutics Q4 2023 Earnings Report
Reported financial results for Q4 2023 and provided an update on late-stage clinical programs for BXCL501.
Key Takeaways
BioXcel Therapeutics reported Q4 2023 financial results, including net revenue from IGALMI of $376,000, R&D expenses of $9.9 million, SG&A expenses of $9.6 million, and a net loss of $22.3 million. The company is focusing on advancing its TRANQUILITY and SERENITY clinical programs.
Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
Research and Development (R&D) expenses were $9.9 million for the fourth quarter of 2023, compared to $32.5 million for the same period in 2022.
Selling, General and Administrative (SG&A) expenses were $9.6 million for the fourth quarter of 2023, compared to $20.7 million for the same period in 2022.
BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
Revenue by Segment
Forward Guidance
The Company estimates that its current cash and cash equivalents will fund its operations through mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...